[go: up one dir, main page]

MX2021006092A - Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos. - Google Patents

Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.

Info

Publication number
MX2021006092A
MX2021006092A MX2021006092A MX2021006092A MX2021006092A MX 2021006092 A MX2021006092 A MX 2021006092A MX 2021006092 A MX2021006092 A MX 2021006092A MX 2021006092 A MX2021006092 A MX 2021006092A MX 2021006092 A MX2021006092 A MX 2021006092A
Authority
MX
Mexico
Prior art keywords
vegf antagonist
eye disorders
angiogenic eye
present
methods
Prior art date
Application number
MX2021006092A
Other languages
English (en)
Inventor
George D Yancopoulos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45507924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021006092(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2021006092A publication Critical patent/MX2021006092A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención provee métodos para tratar trastornos oculares angiogénicos al administrar secuencialmente dosis múltiples de un antagonista de VEGF a un paciente. Los métodos de la presente invención incluyen la administración de dosis múltiples de un antagonista de VEGF a un paciente a una frecuencia de una vez cada 8 o más semanas. Los métodos de la presente invención son útiles para el tratamiento de trastornos oculares angiogénicos tales como degeneración macular relacionada con la edad, retinopatía diabética, edema macular diabético, oclusión de vena retiniana central y neovascularización corneal.
MX2021006092A 2011-01-13 2013-07-04 Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos. MX2021006092A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161432245P 2011-01-13 2011-01-13
US201161434836P 2011-01-21 2011-01-21
US201161561957P 2011-11-21 2011-11-21

Publications (1)

Publication Number Publication Date
MX2021006092A true MX2021006092A (es) 2022-05-18

Family

ID=45507924

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2013007847A MX349901B (es) 2011-01-13 2012-01-11 Uso de un antagonista de factor de crecimiento endotelial vascular para tratar transtornos oculares angiogenicos.
MX2017010249A MX385629B (es) 2011-01-13 2012-01-11 Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.
MX2021006092A MX2021006092A (es) 2011-01-13 2013-07-04 Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2013007847A MX349901B (es) 2011-01-13 2012-01-11 Uso de un antagonista de factor de crecimiento endotelial vascular para tratar transtornos oculares angiogenicos.
MX2017010249A MX385629B (es) 2011-01-13 2012-01-11 Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.

Country Status (13)

Country Link
US (14) US9254338B2 (es)
EP (4) EP3763379A1 (es)
JP (5) JP2014503555A (es)
KR (7) KR20180023015A (es)
CN (1) CN103533950A (es)
AU (5) AU2012205599B2 (es)
BR (1) BR112013017752A8 (es)
CA (1) CA2824422A1 (es)
HK (1) HK1244693A1 (es)
IL (3) IL295359A (es)
MX (3) MX349901B (es)
SG (4) SG191334A1 (es)
WO (1) WO2012097019A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY150400A (en) 2006-04-07 2014-01-15 Aerpio Therapeutics Inc Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
KR20180023015A (ko) 2011-01-13 2018-03-06 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
CN104039351A (zh) 2011-10-13 2014-09-10 阿尔皮奥治疗学股份有限公司 用于治疗血管渗漏综合征和癌症的方法
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016005381A1 (en) * 2014-07-10 2016-01-14 Bayer Pharma Aktiengesellschaft Pdgfrbeta-fc fusion proteins and uses thereof
TWI761959B (zh) * 2014-11-07 2022-04-21 瑞士商諾華公司 治療眼部疾病之方法
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
CN112826934A (zh) * 2014-12-11 2021-05-25 拜耳医药保健有限责任公司 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗
US20180000816A1 (en) * 2015-02-06 2018-01-04 Unity Biotechnology, Inc. Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions
CA2977738A1 (en) * 2015-02-26 2016-09-01 Feramda Ltd. Compositions and combinations for the treatment of angiogenesis diseases and disorders
KR101808234B1 (ko) * 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
WO2017046140A1 (en) * 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
DK3355990T3 (da) 2015-09-30 2019-09-16 Novaliq Gmbh Semifluorinerede forbindelser og disses sammensætninger
US20180353464A1 (en) 2015-11-24 2018-12-13 Indiana University Research And Technology Corporation Composition for blocking angiogenesis
KR102343004B1 (ko) 2015-12-03 2021-12-24 리제너론 파마슈티칼스 인코포레이티드 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법
JP7088454B2 (ja) 2015-12-30 2022-06-21 コディアック サイエンシーズ インコーポレイテッド 抗体および抗体複合体
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
RU2765728C2 (ru) * 2016-05-25 2022-02-02 Сантен Фармасьютикал Ко., Лтд. Применение сиролимуса для лечения экссудативной возрастной макулярной дегенерации с персистирующим отеком
CA3043487A1 (en) 2016-11-21 2018-05-24 Just Biotherapeutics, Inc. Aflibercept formulations and uses thereof
US20190388522A1 (en) * 2017-01-25 2019-12-26 Iconic Therapeutics, Inc. Methods for treating disorders associated with angiogenesis and neovascularization
WO2019099786A1 (en) * 2017-11-16 2019-05-23 Ophthotech Corporation A method for treating or preventing idiopathic polypoidal choroidal vasculopathy (ipcv)
US12178874B2 (en) 2017-11-20 2024-12-31 Just-Evotec Biologics, Inc. Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
WO2019108770A1 (en) * 2017-11-30 2019-06-06 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
EP4495136A3 (en) 2018-01-26 2025-04-23 The Regents of the University of California Methods and compositions for treatment of angiogenic disorders using anti-vegf agents
CN119733046A (zh) * 2018-02-06 2025-04-01 豪夫迈·罗氏有限公司 眼科疾病的治疗
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
JP6938796B2 (ja) * 2018-03-16 2021-09-22 ノバルティス アーゲー 眼疾患を治療するための方法
CN112739323A (zh) 2018-05-10 2021-04-30 瑞泽恩制药公司 含有高浓度vegf受体融合蛋白的制剂
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
EP3856245A4 (en) 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF
US20220143137A1 (en) 2019-02-13 2022-05-12 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
WO2020241660A1 (ja) * 2019-05-28 2020-12-03 学校法人順天堂 糖尿病網膜症の予防又は治療薬
JP2022547681A (ja) * 2019-09-12 2022-11-15 ルピン・リミテッド 眼科使用のためのｖｅｇｆ阻害剤の改変された投薬
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
EP4065150A4 (en) 2019-11-25 2023-12-06 The Regents of the University of California LONG-ACTING VEGF INHIBITORS FOR INTRAVASCULAR NEOVASCULARIZATION
AU2020397053A1 (en) 2019-12-06 2022-06-23 Regeneron Pharmaceuticals, Inc. VEGF mini-traps and methods of use thereof
WO2021112926A1 (en) 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
KR102426802B1 (ko) * 2019-12-23 2022-07-28 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질을 포함하는 신생혈관형성 관련 질환의 예방 및 치료를 위한 약학조성물
US12103960B2 (en) 2020-05-08 2024-10-01 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
CN115697334A (zh) * 2020-06-11 2023-02-03 万能溶剂有限公司 使用ccr3抑制剂改善视网膜相关疾病结果的方法
JPWO2022186335A1 (es) * 2021-03-03 2022-09-09
US20240238427A1 (en) * 2021-04-14 2024-07-18 Kodiak Sciences Inc. Methods of treating an eye disorder
IL308505A (en) * 2021-05-17 2024-01-01 Regeneron Pharma Continuous high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders
WO2024168252A2 (en) * 2023-02-10 2024-08-15 Yale University Use of inhibitors of vegf-c signaling for inhibiting immune responses and increasing gene therapy efficacy
EP4480491A1 (en) * 2023-06-23 2024-12-25 Regeneron Pharmaceuticals, Inc. Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
WO2025036488A1 (en) * 2023-08-17 2025-02-20 Innovent Biologics (Suzhou) Co., Ltd. Methods of treating age-related macular degeneration and diabetic macular edema

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11510170A (ja) 1995-07-27 1999-09-07 ジェネンテック インコーポレーテッド タンパク質の処方
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
KR100659477B1 (ko) 1999-06-08 2006-12-20 리제네론 파라마큐티칼스 인코포레이티드 개선된 약물동태학적 성질을 가지는 변형된 키메라 폴리펩티드
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7396664B2 (en) * 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
EP1409018B1 (en) 2001-07-25 2010-01-06 Facet Biotech Corporation Stable lyophilized pharmaceutical formulation the igg antibody daclizumab
ATE556591T1 (de) 2001-11-08 2012-05-15 Abbott Biotherapeutics Corp Stabile pharmazeutische flüssigformulierung von igg-antikörpern
OA12720A (en) 2001-11-09 2006-06-27 Eyetech Pharmaceuticals Methods for treating ocular neovascular diseases.
JP2003309411A (ja) 2002-04-17 2003-10-31 Alps Electric Co Ltd 複合アンテナ
WO2004072320A2 (en) 2003-02-07 2004-08-26 Pavco, Inc. Use of n-allyl substituted amines and their salts as brightening agents in nickel plating baths
MXPA05008972A (es) 2003-03-28 2005-11-04 Regeneron Pharma Metodos de tratamiento de diabetes por bloqueo de la actividad mediada por factor de crecimiento endotelial vascular.
JP4869064B2 (ja) 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
WO2004103159A2 (en) 2003-05-14 2004-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for modulating endometrium
EP1626989A2 (en) 2003-05-28 2006-02-22 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection by using vegf antagonists
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
WO2005087808A2 (en) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Growth factor binding constructs materials and methods
CN100361710C (zh) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
JP4680997B2 (ja) 2004-06-08 2011-05-11 ツェンドゥー カンホン バイオテクノロジーズ カンパニー リミテッド 血管新生を阻害するキメラタンパク質およびその利用
CN1304427C (zh) 2004-06-08 2007-03-14 成都康弘生物科技有限公司 抑制血管新生的融合蛋白质及其用途
AU2005254058A1 (en) 2004-06-10 2005-12-29 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for the treatment of human cancer
AU2005265071A1 (en) 2004-06-18 2006-01-26 Memorial Sloan-Kettering Cancer Center VEGF inhibitors for the treatment of malignant pleural effusion
EP1771189A2 (en) 2004-07-30 2007-04-11 Regeneron Pharmaceuticals, Inc. Methods of treating type i diabetes by blocking vegf-mediated activity
ES2390676T3 (es) 2004-10-21 2012-11-15 Genentech, Inc. Método para el tratamiento de enfermedades neovasculares intraoculares
WO2006088650A2 (en) * 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
KR101327270B1 (ko) 2005-03-25 2013-11-08 리제네론 파라마큐티칼스 인코포레이티드 혈관내피성장인자 길항제 조제물
MX2008001966A (es) 2005-08-12 2008-03-26 Regeneron Pharma Tratamiento de enfermedades mediante administracion subcutanea de un antagonista vegf.
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
CN100567325C (zh) 2006-03-31 2009-12-09 成都康弘生物科技有限公司 Vegf受体融合蛋白及其在制备治疗眼睛疾病的药物中的应用
PL2944306T3 (pl) 2006-06-16 2021-07-12 Regeneron Pharmaceuticals, Inc. Postacie użytkowe antagonisty VEGF odpowiednie do podawania do ciała szklistego
CA2666709A1 (en) * 2006-11-10 2008-05-29 Genentech, Inc. Method for treating age-related macular degeneration
FR2918279B1 (fr) 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
CN102233132B (zh) 2010-04-28 2013-10-23 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备抑制眼表新生血管生长的药物中的应用
CN102380096B (zh) 2010-08-31 2014-04-30 成都康弘生物科技有限公司 一种含有抑制血管增生的融合蛋白的药物组合物及用途
KR20180023015A (ko) * 2011-01-13 2018-03-06 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
CN103212075B (zh) 2012-01-19 2017-06-27 成都康弘生物科技有限公司 一种含有vegf拮抗剂的滴眼液
CN104804097B (zh) 2014-01-25 2019-02-22 成都康弘生物科技有限公司 一种抑制血管新生或生长的融合蛋白及其用途
TWI761959B (zh) 2014-11-07 2022-04-21 瑞士商諾華公司 治療眼部疾病之方法
WO2019108770A1 (en) 2017-11-30 2019-06-06 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders

Also Published As

Publication number Publication date
BR112013017752A2 (pt) 2017-08-29
US9254338B2 (en) 2016-02-09
US11707506B2 (en) 2023-07-25
US10857205B2 (en) 2020-12-08
HK1244693A1 (en) 2018-08-17
US20180339018A1 (en) 2018-11-29
EP4360709A2 (en) 2024-05-01
US12268730B2 (en) 2025-04-08
MX385629B (es) 2025-03-18
US20250152669A1 (en) 2025-05-15
US20240123030A1 (en) 2024-04-18
US20210308216A1 (en) 2021-10-07
JP2021193115A (ja) 2021-12-23
SG10202111177VA (en) 2021-11-29
AU2012205599A1 (en) 2013-07-18
US10828345B2 (en) 2020-11-10
US10888601B2 (en) 2021-01-12
US20170202911A1 (en) 2017-07-20
US20210085753A1 (en) 2021-03-25
US20210308217A1 (en) 2021-10-07
EP3222285A1 (en) 2017-09-27
IL295359A (en) 2022-10-01
AU2017200290A1 (en) 2017-02-02
KR20240110092A (ko) 2024-07-12
US20210023173A1 (en) 2021-01-28
KR20210030510A (ko) 2021-03-17
US20130295094A1 (en) 2013-11-07
NZ612593A (en) 2015-03-27
US20190046609A1 (en) 2019-02-14
US11975045B2 (en) 2024-05-07
EP3763379A1 (en) 2021-01-13
US11253572B2 (en) 2022-02-22
KR20190049934A (ko) 2019-05-09
CA2824422A1 (en) 2012-07-19
US20190247463A1 (en) 2019-08-15
MX349901B (es) 2017-08-18
JP2014503555A (ja) 2014-02-13
SG191334A1 (en) 2013-08-30
KR20180023015A (ko) 2018-03-06
IL260167A (en) 2018-07-31
US11730794B2 (en) 2023-08-22
BR112013017752A8 (pt) 2018-01-09
EP2663325A1 (en) 2013-11-20
AU2012205599B2 (en) 2016-10-20
AU2024204677A1 (en) 2024-07-25
KR20220097542A (ko) 2022-07-07
KR20200077622A (ko) 2020-06-30
US20160101152A1 (en) 2016-04-14
US11986511B2 (en) 2024-05-21
US10130681B2 (en) 2018-11-20
AU2017200290B2 (en) 2019-01-03
US11559564B2 (en) 2023-01-24
JP2019167366A (ja) 2019-10-03
SG10201802789VA (en) 2018-05-30
US20220273764A1 (en) 2022-09-01
WO2012097019A1 (en) 2012-07-19
AU2021200935A1 (en) 2021-03-11
EP4360709A3 (en) 2024-07-03
SG10201509193UA (en) 2015-12-30
CN103533950A (zh) 2014-01-22
MX2013007847A (es) 2013-07-29
AU2019202260A1 (en) 2019-04-18
US9669069B2 (en) 2017-06-06
KR20140043313A (ko) 2014-04-09
US20210121524A1 (en) 2021-04-29
JP2017061467A (ja) 2017-03-30
IL227160B (en) 2019-02-28
JP2024001190A (ja) 2024-01-09

Similar Documents

Publication Publication Date Title
MX2021006092A (es) Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.
MY176514A (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
MX2016016836A (es) Metodos y dispositivos para tratar trastornos oculares posteriores.
EA201492031A1 (ru) Способы лечения диабетической ретинопатии и других офтальмологических заболеваний
MX2016009331A (es) Composiciones y metodos para tratar enfermedades oculares.
MX2017005875A (es) Metodos para tratar enfermedades oculares.
HK1201438A1 (en) Treatment of ocular disease
EA201491711A1 (ru) Конъюгаты нелинейного мультиблочного сополимера с лекарственным средством для доставки активных агентов
NZ704247A (en) Compositions and treatment for eye diseases and disorders
MX2018000869A (es) Metodos para tratar trastornos asociados con la angiogenesis y la neovascularizacion.
AR090972A1 (es) Metodo para tratar amd en pacientes resistentes a la terapia anti-vegf
PH12014500967A1 (en) A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent
EA201290603A1 (ru) Способ лечения
WO2014184576A3 (en) Delivery of a therapeutic agent to the cerebral cortex by administering a viral vector by convection enhanced diffusion into the white matter of the brain
PH12020551015A1 (en) Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability
MX391627B (es) Aplicación cuantitativa periorbital de fármacos oftalmológicos.
EP4245295A3 (en) Compounds and pharmaceutical compositions for use in treating retina-associated disease using ccr3-inhibitors
MX2019011242A (es) Farmacos y composiciones para el tratamiento de trastornos oculares.
HRP20192256T1 (hr) Uporaba kabergolina u liječenju očnih bolesti uzrokovanih povišenim čimbenikom vaskularnog endotelnog rasta
PH12020550722A1 (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
HK1189820A (en) Use of a vegf antagonist to treat angiogenic eye disorders
AR102494A1 (es) Métodos para tratar enfermedades oculares
BR112017007102A2 (pt) uso de um medicamento no tratamento de patologias da córnea, composição oftálmica para uso de um medicamento no tratamento de doenças da córnea e método para preparar a composição oftálmica
Park et al. Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion
Dunn Prednisolone acetate